Skip to main content
Fig. 3 | BMC Urology

Fig. 3

From: Clinical characteristics of patients with metastatic castration-resistant prostate cancer after treatment with combined androgen blockade

Fig. 3

A Kaplan–Meier estimates of overall survival after CRPC with first-line CRPC treatments. B The duration of abiraterone treatment is compared according to the timing of its use (before and after docetaxel). *p < 0.05, Student’s t-tests. Bars, SD. Correlation of best PSA response to abiraterone with docetaxel (C) and cabazitaxel (D)

Back to article page

BMC Urology

ISSN: 1471-2490

Contact us